Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 2
2009 1
2010 3
2012 2
2017 4
2018 2
2019 6
2020 1
2021 5
2022 1
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Kasai T, Mori K, Nakamura Y, Seki N, Ichikawa Y, Saito H, Kondo T, Nishikawa K, Otsu S, Bessho A, Tanaka H, Yamaguchi H, Kaburagi T, Imai H, Mori K, Ohtake J, Okamoto H. Kasai T, et al. Among authors: ichikawa y. Cancer Med. 2023 Jul;12(14):14988-14999. doi: 10.1002/cam4.6135. Epub 2023 May 24. Cancer Med. 2023. PMID: 37226421 Free PMC article. Clinical Trial.
Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A, Agemi Y, Shimokawa T, Otani S, Nakahara Y, Naoki K, Yomota M, Hosomi Y, Takiguchi Y, Tokito T, Ando S, Okamoto H. Ichikawa Y, et al. Transl Cancer Res. 2023 Apr 28;12(4):873-886. doi: 10.21037/tcr-22-2144. Epub 2023 Mar 23. Transl Cancer Res. 2023. PMID: 37180670 Free PMC article.
Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine.
Amano M, Otsu S, Ichikawa Y, Higashi-Kuwata N, Matsushita S, Shimada S, Mitsuya H. Amano M, et al. Among authors: ichikawa y. J Infect Dis. 2022 Dec 28;227(1):161-163. doi: 10.1093/infdis/jiac393. J Infect Dis. 2022. PMID: 36134611 Free PMC article. No abstract available.
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K, Shimizu Y, Fujiwara A, Takamatsu Y, Ichikawa Y, Nishimura H, Kinoshita M, Matsumoto S, Gatanaga H, Yoshimura K, Oka SI, Mikami A, Sugiura W, Sato T, Yoshida T, Shimada S, Mitsuya H. Maeda K, et al. Among authors: ichikawa y. Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y. Sci Rep. 2021. PMID: 34819514 Free PMC article.
Paraneoplastic IgA Vasculitis in an Adult with Lung Adenocarcinoma.
Ota S, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Sasajima Y, Seki N. Ota S, et al. Among authors: ichikawa y. Intern Med. 2018 May 1;57(9):1273-1276. doi: 10.2169/internalmedicine.9651-17. Epub 2017 Dec 27. Intern Med. 2018. PMID: 29279496 Free PMC article.
36 results